An Indiana not-for-profit has dropped the price of a drug for multi-drug resistant tuberculosis roughly 90 percent after re-acquiring rights to the medicine from Rodelis Therapeutics.
Anthem Inc. CEO Joseph Swedish and Aetna Inc. CEO Mark Bertolini will tell federal lawmakers Tuesday that the deals are necessary to succeed in a changing health-care landscape.
It looks like Eli Lilly and Co. finally has a drug that can replace its former stars Zyprexa and Cymbalta. The most bullish analysts think Jardiance can surpass those $5 billion-a-year blockbusters.
Pharmaceutical industry members are likely to dislike the proposal, which would require them disclose how much they spend on research and development, production, and sales and marketing.
When hospitals employ doctors—which is now the norm in central Indiana—more of those doctors’ patients end up going to hospitals with higher costs and poorer quality, according to a new study.
Four of the 10 metro areas that will see the biggest decrease in competition from the Anthem-Cigna merger are in Indiana, according to an analysis by the American Medical Association—with Indianapolis facing the second-biggest impact among all of Anthem’s markets nationwide.
A shortage of primary care physicians and emerging alternatives such as retail clinics and smartphone apps are changing the way patients access the U.S. health care system.
On Oct. 1, the nation’s physicians and hospitals must start using a massive new coding system to describe your visit on insurance claims so they get paid.
CEO Bryan Mills has set a goal to make 75 percent of revenue—or $1.5 billion a year—be covered by value-based contracts—which means Community would be rewarded for keeping patients out of the hospital. A new venture is Mills’ strategy to get there.
More paying customers helped Community Health Network pull in $47 million in second-quarter profits, a story being repeated at not-for-profit hospitals around the country as Obamacare has boosted the number of insured customers to unprecedented highs.
Eli Lilly and Co. won a court ruling that will keep generic versions of the chemotherapy drug Alimta off the U.S. market until a patent expires in 2022.
Eli Lilly and Co. didn’t win approval for a new drug last week. But its latest study of an existing diabetes drug could create a blockbuster in its own right—adding as much as $1 billion a year to the coffers of the Indianapolis-based drugmaker.
I raise for consideration the notion of “balanced” health plans that place priority on prevention and access. Preventive care is inexpensive, while chronic disease treatments and emergency-room visits are not.
The Food and Drug Administration on Tuesday approved the first prescription drug designed to boost sexual desire in women, a milestone long sought by a pharmaceutical industry eager to replicate the blockbuster success of impotence drugs for men.
The new head of research at the Indiana University School of Medicine thinks the institution is missing out on the more than $6 billion spent each year in the United States on clinical trials.
The federal government says it wants Lance Armstrong's medical records from his 1996 cancer treatments because they could prove just how far he was willing to go to conceal performance-enhancing drug use from the public and his sponsors.
Mike Meadows helped with the massive task of taking Lilly’s IT organization through a downsizing that reduced expenses about 40 percent—with no significant IT service disruptions.
Dr. John Sturman overprescribed narcotics to patients at a clinic he operated at Indiana University Hospital, Marion County prosecutors contend. The deaths occurred in 2010 and 2011.
